Combined delivery and magnetic resonance imaging of neural cell adhesion molecule-targeted doxorubicin-containing liposomes in experimentally induced Kaposi's sarcoma

Cancer Research

Volumn 70, Issue 6, 2010, Pages 2180-2190

  Grange, Cristina ^a   Geninatti Crich, Simonetta ^b   Esposito, Giovanna ^b   Alberti, Diego ^b   Tei, Lorenzo ^c   Bussolati, Benedetta ^a   Aime, Silvio ^b   Camussi, Giovanni ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; GADOLINIUM; LIPOSOME; MACROGOL; NERVE CELL ADHESION MOLECULE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DEATH; CONTROLLED STUDY; DRUG TARGETING; ELECTRON MICROSCOPY; EXTRACELLULAR SPACE; IN VITRO STUDY; IN VIVO STUDY; KAPOSI SARCOMA; MALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SCID MOUSE; TUMOR CELL; TUMOR VASCULARIZATION;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CONTRAST MEDIA; DOXORUBICIN; HETEROCYCLIC COMPOUNDS; HUMANS; LIPOSOMES; MAGNETIC RESONANCE IMAGING; MALE; MICE; MICE, SCID; NEURAL CELL ADHESION MOLECULES; ORGANOMETALLIC COMPOUNDS; POLYETHYLENE GLYCOLS; SARCOMA, KAPOSI;

EID: 77950273997     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-2821     Document Type: Article

References (48)

1. Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2002;2:750-763
2. Haley B, Frenkel E. Nanoparticles for drug delivery in cancer treatment. Urol Oncol 2008;26:57-64.
3. Schiffelers RM, Storm G. Liposomal nanomedicines as anticancer therapeutics: beyond targeting tumor cells. Int J Pharm 2008;364: 258-264
4. Li C, Penet MF, Winnard P, Jr., Artemov D, Bhujwalla ZM. Image-guided enzyme/prodrug cancer therapy. Clin Cancer Res 2008;14: 515-522
5. Koning GA, Krijger GC. Targeted multifunctional lipid-based nanocarriers for image-guided drug delivery. Anticancer Agents Med Chem 2007;7:425-440
6. Schwendener RA. Liposomes in biology and medicine. Adv Exp Med Biol 2007;620:117-128
7. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000;65:271-284
8. Greish K. Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines. J Drug Target 2007;15:457-464
9. Romberg B, Hennink WE, Storm G. Sheddable coatings for long-circulating nanoparticles. Pharm Res 2008;25:55-71.
10. Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine 2006;1:297-315.
11. Garde SV, Forté AJ, Ge M, et al. Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects. Anticancer Drugs 2007; 18:1189-1200
12. Gabizon A, Martin F. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours. Drugs 1997;54: 15-21.
13. Main C, Bojke L, Griffin S, et al. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation. Health Technol Assess 2006;10:1-132.
14. Ulrich-Pur H, Kornek GV, Haider K, et al. Phase II trial of pegylated liposomal doxorubicin (Caelyx) plus gemcitabine in chemotherapeutically pretreated patients with advanced breast cancer. Acta Oncol 2007;46:208-213
15. Wagner S, Peters O, Fels C, et al. Pegylated-liposomal doxorubicin and oral topotecan in eight children with relapsed high-grade malignant brain tumors. J Neurooncol 2008;86:175-181
16. Piguet AC, Semela D, Keogh A, et al. Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma. J Hepatol 2008;49:78-87.
17. Northfelt DW, Martin FJ, Working P, et al. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. J Clin Pharmacol 1996;36:55-63.
18. Allen TM. Long-circulating (sterically stabilized) liposomes for targeted drug delivery. Trends Pharmacol Sci 1994;15:215-220
19. Villares GJ, Zigler M, Wang H, et al. Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA. Cancer Res 2008; 68:9078-9086
20. Gosk S, Moos T, Gottstein C, Bendas G. VCAM-1 directed immuno-liposomes selectively target tumor vasculature in vivo. Biochim Biophys Acta 2008;1778:854-863
21. Roth P, Hammer C, Piguet AC, Ledermann M, Dufour JF, Waelti E. Effects on hepatocellular carcinoma of doxorubicin-loaded immunoliposomes designed to target the VEGFR-2. J Drug Target 2007;15: 623-631
22. Zhao H, Wang JC, Sun QS, Luo CL, Zhang Q. RGD-based strategies for improving antitumor activity of paclitaxel-loaded liposomes in nude mice xenografted with human ovarian cancer. J Drug Target 2009;17:10-18
23. Anhorn MG, Wagner S, Kreuter J, Langer K, von Briesen H. Specific targeting of HER2 overexpressing breast cancer cells with doxorubicin-loaded trastuzumab-modified human serum albumin nanoparticles. Bioconjug Chem 2008;19:2321-2331
24. Chang DK, Lin CT, Wu CH, Wu HC. A novel peptide enhances therapeutic efficacy of liposomal anti-cancer drugs in mice models of human lung cancer. PLoS ONE 2009;4.
25. Bussolati B, Grange C, Bruno S, et al. Neural-cell adhesion molecule (NCAM) expression by immature and tumor-derived endothelial cells favors cell organization into capillary-like structures. Exp Cell Res 2006;312:913-924
26. Rønn LCB, Olsen M, Ostergaard S, et al. Identification of a neuritogenic ligand of the neural cell adhesion molecule using a combinatorial library of synthetic peptides. Nat Biotechnol 1999;17:1000-1005
27. Walsh FS, Doherty P. Neural cell adhesion molecules of the immunoglobulin superfamily: role in axon growth and guidance. Annu Rev Cell Dev Biol 1997;13:425-456
28. Jensen M, Berthold F. Targeting the neural cell adhesion molecule in cancer. Cancer Lett 2007;258:9-21.
29. Rønn LC, Berezin V, Bock E. The neural cell adhesion molecule in synaptic plasticity and ageing. Int J Dev Neurosci 2000;18:193-199
30. Kiryushko D, Kofoed T, Skladchikova G, Holm A, Berezin V, Bock E. Identification of a neuritogenic ligand of the neural cell adhesion molecule using a combinatorial library of synthetic peptides. J Biol Chem 2003;278:12325-12334
31. Geninatti Crich S, Bussolati B, Tei L, et al. Magnetic resonance visualization of tumor angiogenesis by targeting neural cell adhesion molecules with the highly sensitive gadolinium-loaded apoferritin probe. Cancer Res 2006;66:9196-9201
32. Anelli PL, Lattuada L, Lorusso V, Schneider M, Tournier H, Uggeri F. Mixed micelles containing lipophilic gadolinium complexes as MRA contrast agents. MAGMA 2001;12:114-120
33. Olson F, Hunt CA, Szoka FC, Vail WJ, Papahadjopoulos D. Preparation of liposomes of defined size distribution by extrusion through polycarbonate membranes. Biochim Biophys Acta 1979;557:9-23.
34. Abraham SA, Waterhouse DN, Mayer LD, Cullis PR, Madden TD, Bally MB. The liposomal formulation of doxorubicin. Methods Enzymol 2005;391:71-97.
35. Hermanson GT. Bioconjugate techniques. Pyridyl disulfides. San Diego (CA): Academic Press; 1996, p. 151.
36. Deregibus MC, Cantaluppi V, Doublier S, et al. HIV-1-Tat protein activates phosphatidylinositol 3-kinase/AKT-dependent survival pathways in Kaposi's sarcoma cells. J Biol Chem 2002;277: 25195-25202
37. Bussolati B, Deambrosis I, Russo S, Deregibus MC, Camussi G. Altered angiogenesis and survival in human tumor-derived endothelial cells. FASEB J 2003;17:1159-1161
38. Camussi G, Kerjaschki D, Gonda M, et al. Expression and modulation of surface antigens in cultured rat glomerular visceral epithelial cells. J Histochem Cytochem 1989;37:1675-1687
39. Goren D, Horowitz AT, Tzemach D, Tarshish M, Zalipsky S, Gabizon A. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Clin Cancer Res 2000;6: 1949-1957
40. Fossheim SL, Fahlvik AK, Klaveness J, Muller RN. Paramagnetic liposomes as MRI contrast agents: influence of liposomal physicochemical properties on the in vitro relaxivity. Magn Reson Imaging 1999;17:83-89.
41. Terreno E, Geninatti Crich S, Belfiore S, et al. Effect of the intracellular localization of a Gd-based imaging probe on the relaxation enhancement of water protons. Magn Reson Med 2006;55:491-497
42. Esposito G, Geninatti Crich S, Aime S. Efficient cellular labeling by CD44 receptor-mediated uptake of cationic liposomes functionalized with hyaluronic acid and loaded with MRI contrast agents. Chem-MedChem 2008;3:1858-1862
43. Nakamura S, Salahuddin SZ, Biberfeld P, et al. Kaposi's sarcoma cells: long-term culture with growth factor from retrovirus-infected CD4+ T cells. Science 1988;242:426-430
44. Mitsuyasu RT. Update on the pathogenesis and treatment of Kaposi sarcoma. Curr Opin Oncol 2000;12:174-180
45. Albini A, Paglieri I, Orengo G, et al. The β-core fragment of human chorionic gonadotrophin inhibits growth of Kaposi's sarcomaderived cells and a new immortalized Kaposi's sarcoma cell line. AIDS 1997;11:713-721
46. Sharpe M, Easthope SE, Keating GM, Lamb HM. Polyethylene glycol-liposomal doxorubicin: a review of its use in the management of solid and haematological malignancies and AIDS-related Kaposi's sarcoma. Drugs 2002;62:2089-2126
47. Krown SE, Northfelt DW, Osoba D, Stewart JS. Use of liposomal anthracyclines in Kaposi's sarcoma. Semin Oncol 2004;31:36-52.
48. Vail DM, Amantea MA, Colbern GT, Martin FJ, Hilger RA, Working PK. Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studies. Semin Oncol 2004;31:16-35.